Uncategorized

Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination

Medivir AB announces that a poster entitled ‘A triple combination of fostrox with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo,’ will be presented at the American Association for Cancer Research Annual Meeting by Fredrik Öberg, CSO at Medivir.

Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination Read More »

Scroll to Top